Focused On-demand Library for Transmembrane 4 L6 family member 20

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q53R12

UPID:

T4S20_HUMAN

Alternative names:

Alternative UPACC:

Q53R12; B2RP42; Q5U609; Q6UWS1; Q9H5X9

Background:

Transmembrane 4 L6 family member 20 (TM4SF20) is a polytopic transmembrane protein known for its role in inhibiting the regulated intramembrane proteolysis (RIP) of CREB3L1, thus preventing collagen synthesis activation. This process is influenced by ceramide, which can alter TM4SF20's membrane topology and stimulate CREB3L1's RIP activation. The unique 'regulated alternative translocation' (RAT) mechanism is pivotal in TM4SF20's function, showcasing its complex role in cellular processes.

Therapeutic significance:

TM4SF20's involvement in Specific language impairment 5, a disorder marked by delayed speech acquisition and potential cerebral abnormalities, underscores its clinical relevance. Understanding TM4SF20's function could pave the way for innovative therapeutic strategies targeting speech and developmental disorders, offering hope for affected individuals.